体外研究
Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) treatment significantly decreased the viability of HT-29 colon cancer cells in a time- and concentration-dependent. The respective IC
50
values for 24 and 48 h of Hexahydrocurcumin exposureare 77.05 and 56.95, respectively.
Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) combined with 5-fluorouracil (5-FU; 5 µM) markedly reduces the COX-2 expression. The level of COX-1 is not altered.
Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) combined with 5-fluorouracil (5-FU; 5 µM) markedly reduces the COX-2 protein. The level of COX-1 protein is not altered.
Hexahydrocurcumin (7-14 μM; 24 hours) attenuates lipopolysaccharide (LPS)-elicited increase of prostaglandin E
2
(PGE
2
) in murine macrophages (RAW 264.7) in a concentration-dependent manner.
Cell Viability Assay
Cell Line:
HT-29 cells
Concentration:
0 µM, 5 µM, 10 µM, 25 µM
Incubation Time:
24 hours or 48 hours
Result:
Significantly decreased the viability of HT-29 colon cancer cells.
RT-PCR
Cell Line:
HT-29 cells
Concentration:
25 µM
Incubation Time:
24 hours
Result:
Combined with 5-fluorouracil (5-FU; 5 µM) markedly reduced the COX-2 expression.
Western Blot Analysis
Cell Line:
HT-29 cells
Concentration:
25 µM
Incubation Time:
24 hours
Result:
Combined with 5-fluorouracil (5-FU; 5 µM) markedly reduced the COX-2 protein.
体内研究
Hexahydrocurcumin (50 mg/kg; oral administration; daily; for 16 weeks; male Wistar rats) treatment significantly reduces the numbers of aberrant crypt foci (ACF) in colon cancer rats. Hexahydrocurcumin also markedly decreases COX-2 protein expression. The levels of COX-1 protein is not different from normal rats.
Animal Model:
Male Wistar rats (100-120 g) injected with dimethylhydrazine (DMH)
Dosage:
50 mg/kg
Administration:
Oral administration; daily; for 16 weeks
Result:
Significantly reduced the numbers of ACF in colon cancer rats. Also markedly decreased COX-2 protein expression.
